Advertisement

Topics

The Angelman Syndrome Foundation Company Profile

10:28 EST 14th December 2018 | BioPortfolio


News Articles [1044 Associated News Articles listed on BioPortfolio]

Ovid’s Angelman Syndrome Therapy Hits Prespecified Endpoint Phase II Trial, Shares Drop Significa...

Ovid Therapeutics is shouting good news from the rooftops regarding its mid-stage Angelman Syndrome study, but investors are not convinced.

Ovid's Angelman syndrome drug shows mixed results in Phase 2

OV101 is trying to be the first treatment for Angelman syndrome, a rare genetic disorder. While it achieved its primary clinical trial goal focused on safety, the efficacy endpoints were mixed, leadin...

Ovid falls on Phase II data for Angelman syndrome candidate

Neuralstem Announces NSI-189 Granted Orphan Drug Designation from the U.S. FDA for the Treatment of Angelman Syndrome

GERMANTOWN, Md., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell te...

Ovid's Angelman syndrome candidate misses behavior, sleep and gait endpoints in Phase II

$OVID Announces Plans to Move into a Phase 3 Trial in Pediatric Patients Based on End-of-Phase 2 Meeting for OV101 in Angelman Syndrome https://globenewswire.com/news-release/2018/12/06/1663049/0/en/Ovid-Therapeutics-Announces-Plans-to-Move-into-a-Phase-3

$OVID Announces Plans to Move into a Phase 3 Trial in Pediatric Patients Based on End-of-Phase 2 Meeting for OV101 in Angelman Syndrome https://globenewswire.com/news-release/2018/12/06/1663049/0/en...

Ovid Therapeutics Announces Positive Topline Data from Phase 2 STARS Trial of OV101 for the Treatment of Angelman Syndrome

-- OV101 achieved primary endpoint of safety and tolerability -- -- Robust and statistically significant improvement (p=0.0006) in the first prespecified efficacy endpoint (CGI-I) observed at 12 we...

Can Genetic Therapy Help Kids with Angelman Syndrome Overcome Seizures?

NewsAngelman syndrome is a genetic disease with no cure. Children grow up with severe intellectual disabilities and a range of other problems, arguably the worst of which are epileptic seizures.

Drugs and Medications [450 Associated Drugs and Medications listed on BioPortfolio]

Esika [Ventura Corporation (San Juan, P.R)]

ēsika 3-in-1 Pro Make Up Foundation SPF 20

Sheer cover mineral foundation [Guthy-Renker LLC]

Sheer Cover Mineral Foundation SPF-15

Cle de peau beaute silky foundation i [SHISEIDO CO., LTD.]

CPB Silky Cream Foundation I

Cle de peau beaute foundation i [SHISEIDO CO., LTD.]

cle de peau BEAUTE Cream Foundation I

Shiseido perfect refining foundation [SHISEIDO AMERICA INC.]

SHISEIDO Perfect Refining Foundation

PubMed Articles [2586 Associated PubMed Articles listed on BioPortfolio]

Social-emotional processing in nonverbal individuals with Angelman syndrome: evidence from brain responses to known and novel names.

The combination of intellectual, communicative and motor deficits limits the use of standardised behavioural assessments in individuals with Angelman syndrome (AS). The current study aimed to objectiv...

A proteasomal partner goes missing in Angelman syndrome.

Loss-of-function mutations in the UBE3A ubiquitin ligase are associated with Angelman syndrome (AS), a severe neurologic disorder. A new study defines the role of mutations in an N-terminal "AZUL" dom...

Abnormal coherence and sleep composition in children with Angelman syndrome: a retrospective EEG study.

Angelman syndrome (AS) is a neurodevelopmental disorder characterized by intellectual disability, speech and motor impairments, epilepsy, abnormal sleep, and phenotypic overlap with autism. Individual...

Generation of an iPSC line of a patient with Angelman syndrome due to an imprinting defect.

Angelman syndrome (AS) is a neurodevelopmental disorder with leading symptoms of happy demeanor, intellectual disability, ataxia and seizures. AS can be caused by genetic and epigenetic aberrations, r...

Quantitative proteomics reveals neuronal ubiquitination of Rngo/Ddi1 and several proteasomal subunits by Ube3a, accounting for the complexity of Angelman syndrome.

Angelman syndrome is a complex neurodevelopmental disorder caused by the lack of function in the brain of a single gene, UBE3A. The E3 ligase coded by this gene is known to build K48-linked ubiquitin ...

Clinical Trials [4332 Associated Clinical Trials listed on BioPortfolio]

Study on the Brain Network of Angelman Syndrome

The aims of study on Angelman syndrome: (1)establish the Angelman syndrome database (2)to study the brain Network of Angelman Syndrome Based on Multi-modal Brain Image and Neural-EEG Data

Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome

This study is designed to determine the highest dose of levodopa/carbidopa that can be tolerated without any serious side effects by children with Angelman syndrome. It has been hypothesi...

Characterization of Angelman Syndrome

Angelman Syndrome (AS) is a developmental disorder that is caused by a deficiency of a maternally transmitted gene. It is inherited at birth, and affects movement, speech, and social demea...

Angelman Syndrome Italian Registry

The Italian Angelman Registry is a national registry for patients with Angelman Syndrome. No experimental intervention is involved in participation. The data provided are stored in the reg...

Dietary Supplements for the Treatment of Angelman Syndrome

Angelman syndrome (AS) is a complex genetic disorder that affects the nervous system. The purpose of this study is to determine the effectiveness of certain dietary supplements in treating...

Companies [1514 Associated Companies listed on BioPortfolio]

Angelman Syndrome Foundation

Since 1996, the Angelman Syndrome Foundation has funded 59 research grants totaling more than $3.5 million. The Angelman Syndrome Foundation has awarded a majority of these funds ($3.3 million) beginn...

Foundation for Angelman Syndrome Therapeutics (FAST)

Angelman Syndrome (AS) was first described by Dr. Harry Angelman in 1965. Common symptoms include developmental delay and intellectual disabilities, happy demeanor, movement and balance disorder, seve...

The Angelman Syndrome Foundation

Sjogren's Syndrome Foundation

Founded in 1983, the Sjogren's Syndrome Foundation (SSF) provides patients with practical information and coping strategies that minimize the effects of Sjogren's syndrome. In addition, the Foundation...

Global Down Syndrome Foundation

The Global Down Syndrome Foundation is a public non-profit 501(c)(3) dedicated to significantly improving the lives of people with Down syndrome through research, medical care, ed...

More Information about "The Angelman Syndrome Foundation" on BioPortfolio

We have published hundreds of The Angelman Syndrome Foundation news stories on BioPortfolio along with dozens of The Angelman Syndrome Foundation Clinical Trials and PubMed Articles about The Angelman Syndrome Foundation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of The Angelman Syndrome Foundation Companies in our database. You can also find out about relevant The Angelman Syndrome Foundation Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record